Roivant Sciences Ltd. Overview
Pro stress-test →Roivant (Nasdaq: ROIV) is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. The company advances its pipeline by creating nimble subsidiaries or "Vants" to develop and commercialize medicines and technologies.
Strategic Profile
Pro stress-test →Roivant's pipeline includes brepocitinib, a potent small molecule inhibitor of JAK1 and TYK2 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. Roivant Sciences has drawn fresh attention after announcing a US$2.25b global settlement with Moderna that ends ongoing patent litigation, along with positive IMVT-1402 rheumatoid arthritis data and Breakthrough Therapy Designation for brepocitinib.
Competitive Landscape
Pro stress-test →Roivant competes in the autoimmune therapeutics space against established companies like Abbvie (JAK inhibitors), Roche/Genentech (FcRn antibodies), and Johnson & Johnson (immunology), along with emerging biotech players. Its differentiated dual JAK1/TYK2 mechanism and subsidiary-based structure provide competitive positioning, though execution risk on Phase 3 trials and regulatory approvals remains material.
Industry Context
Roivant Sciences Ltd. operates in Autoimmune therapeutics.
Key facts
Founded: 2014 · Headquarters: Hamilton, Bermuda · Employees: N/A · Revenue: $8.26 million (FY 2026) · Market cap: N/A